Humanwell Healthcare (Group) Co.,Ltd. (SHSE: 600079)
Health Care · Pharmaceuticals · CN
CN¥17.89
-0.56% today · -13.9% 1Y
Humanwell Healthcare (Group) Co.,Ltd. (SHSE: 600079) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $4.34B and employs 17,153 people.
Over the last twelve months the share price has lost 13.9%, trading between 16.03 and 23.66.
Tweenvest scores Humanwell Healthcare (Group) Co.,Ltd. across four factors: quality 79/100, value 76/100, growth 62/100, dividend 36/100. Its strongest factor is quality.
600079 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.34B
- Revenue (TTM)
- $3.47B
- P/E
- 15.29
- EPS
- 1.17
- Dividend yield
- 2.68%
- Beta (5Y)
- 0.34
- 52-week high
- CN¥23.66
- 52-week low
- CN¥16.03
- Avg volume (3M)
- —
- Shares outstanding
- 1.63B
- Employees
- 17,153
- Next earnings
- —
About Humanwell Healthcare (Group) Co.,Ltd.
Humanwell Healthcare (Group) Co.,Ltd. operates internationally, delivering a wide spectrum of healthcare solutions across regions including the Asia Pacific, North America, and Africa. The company's diverse product range features pharmaceuticals for pain management, such as anesthetics and analgesics, alongside a significant focus on women's health, providing items for reproductive planning, emergency contraception, and general wellness. They also produce central nervous system (CNS) medications addressing conditions like bronchitis, migraines, dysmenorrhea, neuralgia, epilepsy, acute and chronic cerebrovascular diseases, brain injuries, and peripheral vascular disorders. Furthermore, their offerings extend to traditional herbal remedies for common ailments such as colds and flu, rheumatoid arthritis, dermatological concerns, hepatitis, urinary tract infections, and memory impairment. Humanwell also supplies anti-infective agents, a variety of over-the-counter (OTC) drugs for digestive complaints, cold and flu relief, anti-inflammatory purposes, infections, and nutritional supplements. Complementing these, they offer specific treatments aimed at cardiovascular, gastrointestinal, and reproductive system diseases. Established in Wuhan, China, in 1993, the enterprise was initially known as Wuhan Humanwell Healthcare (Group) Co., Ltd. before adopting its current name, Humanwell Healthcare (Group) Co.,Ltd., in March 2013.
- ISIN
- CNE000000QW6
- Founded
- 1988
- Listed since
- Jun 6, 1997
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.